Programs in this category typically work with GLP-1 receptor agonists such as semaglutide and the dual agonist tirzepatide, dispensed either as FDA-approved brand products or compounded preparations
Reports of skin irritation and blisters with some patch products add safety concerns to the effectiveness questions
The expansion of diabetes management programs, increasing obesity treatment initiatives, and strong clinical evidence supporting long-term outcomes have reinforced the segments leadership position
Yilmaz M, Kantarjian H, Muftuoglu M, Kadia T, Konopleva M, Borthakur G, DiNardo C, Pemmaraju N, Short NJ, Alvarado Y, Montalban-Bravo G, Jurisprudenica C, Pike A, Ohanian M, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M , Daver N